Ferring Pharmaceuticals will expand its biologics capabilities at its headquarters and manufacturing site in Saint-Prex, Switzerland.
Ferring Pharmaceuticals, a biopharmaceutical company specializing in reproductive medicine, announced on Feb. 14, 2018 that it is making a CHF 30-million (US$32 million ) investment in a new biotech center to expand its capabilities in biologics
The center, which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland, over the course of three years, will incorporate discovery and development capabilities for monoclonal antibodies (mAbs) as well as biologics manufacturing capabilities. The active pharmaceutical ingredient for the company’s fertility treatment, Rekovelle (follitropin delta), will also be manufactured at the new center.
“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology, and urology,” said Michel Pettigrew, president of the executive board and chief operating officer at Ferring, in a company press release. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas and will open up additional opportunities for Ferring to help people live better lives.”
Additionally, in early 2018, Ferring announced a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform to discover new human mAbs and accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology, and gastroenterology. Together, these investments significantly expand Ferring’s growing capabilities in biologics, according to the company.
Source: Ferring
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.